Prospects for GlaxoSmithKline's therapeutic cancer vaccine MAGE-A3 are looking increasingly shaky after a second negative phase III trial, this time in lung cancer.
The MAGRIT study showed that the vaccine was unable to improve disease-free survival (DFS) compared to placebo in patients with non-small cell lung cancer (NSCLC) whose tumours carried the MAGE-A3 antigen, regardless of whether or not they were receiving chemotherapy.
From here: http://www.pmlive.com/pharma_news/gsks_cancer_vaccine_flunks_another_trial_554491
No comments:
Post a Comment